Michelle Corral
Vice President of Investor Relationship & Corporate Communications
Hi, everyone, and thank you for joining us today. I’m Michelle Corral, Vice President of Corporate Communications and Investor Relations at Tenaya. Today, we are excited to present initial data from Cohort 1 of the RIDGE-1 Phase Ib/II clinical trial of TN-401 gene therapy for the potential treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy or otherwise known as ARVC.
On the call with me are Faraz Ali, Tenaya’s Chief Executive Officer; Dr. Kathy Ivey, our SVP of Research; and Dr. Whit Tingley, Tenaya’s Chief Medical Officer.
While the data we are disclosing will be described in full verbally, please note that during the course of today’s call, we will be making references to slides. A PDF file of these slides is available on the Tenaya website in the IR section under Events and Presentations.
As a reminder, the information discussed during this call will include forward-looking statements, which represent the company’s view as of today, December 11, 2025. These statements involve certain assumptions, and we caution investors not to place undue reliance on this information. Please refer to today’s press release as well as our filings with the SEC for information concerning risk factors that could cause actual results to differ materially from those expressed or implied by these statements.
In addition, I’d like to remind folks that we are unable to take questions on today’s call due to the launch
